The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension...
Date First Received: April 10, 2006
Last Updated: February 29, 2008
Verified by: Alcon Research, February 2008
Clinical Trial Phase: Phase 3 | Start Date:
Overall Status: Completed
Brief Summary
Condition Keyword(s):
Intervention(s):
The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Intervention(s) in this Clinical Trial
- Drug: Brinzolamide 1%/Timolol 0.5%, Brinzolamide 1%, Timolol 0.5%
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Over 18 with open-angle glaucoma
Exclusion Criteria:
- Under 18
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Alcon Research
Additional Information
Information obtained from ClinicalTrials.gov on October 06, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00314158
Study ID Number: C-05-24
ClinicalTrials.gov Identifier: NCT00314158
Health Authority: United States: Food and Drug Administration
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
